Sanofi's decision to end development of the drug in myasthenia gravis may lie in the changing landscape of therapies for the disease, including the approval of Argenx' neonatal FC receptor (FcRn ...
HAYWARD, CA, USA I October 02, 2024 I Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing ...
Some results have been hidden because they may be inaccessible to you